| Literature DB >> 25122163 |
Caroline M L Williams1, Eddy S G Cheah1, Joanne Malkin2, Hemu Patel3, Jacob Otu4, Kodjovi Mlaga4, Jayne S Sutherland4, Martin Antonio4, Nelun Perera3, Gerrit Woltmann5, Pranabashis Haldar6, Natalie J Garton1, Michael R Barer2.
Abstract
BACKGROUND: Although tuberculosis is transmitted by the airborne route, direct information on the natural output of bacilli into air by source cases is very limited. We sought to address this through sampling of expelled aerosols in face masks that were subsequently analyzed for mycobacterial contamination.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25122163 PMCID: PMC4133242 DOI: 10.1371/journal.pone.0104921
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Schematic of mask processing for phage assay.
See text for abbreviations.
Figure 2FFP30 mask with filter adapted for sampling.
SERIES 1, PHAGE ASSAYS ON SURGICAL MASKS.
| Patient No. | am/pm Sample | Sampling Period (min) | Phage Assay |
| 1 | am | 300 | - |
| 1 | pm | 120 | - |
| 2 | pm | 120 | - |
| 3 | U | 10 | + |
| 3 | U | U | + |
| 4 | U | 60 | - |
| 4 | U | 60 | + |
| 5 | am | 30 | + |
| 5 | pm | 30 | - |
| 6 | am | 120 | + |
| 7 | U | 50 | + |
| 7 | U | 25 | + |
| 8 | U | 40 | - |
| 9 | U | 60 | + |
| 10 | am | 30 | - |
| 10 | pm | 50 | - |
| 11 | U | U | - |
| 12 | pm | 40 | + |
| 13 | am | 60 | + |
| 13 | pm | 60 | + |
| 14 | am | 60 | + |
| 14 | pm | 60 | + |
| 15 | am | 60 | + |
| 15 | pm | 60 | + |
| 16 | am | 45 | + |
| 16 | pm | 45 | + |
| 17 | am | 30 | - |
| 17 | pm | 30 | - |
ND = not done; U = not recorded.
*M. kansasii isolated.
M. aviumisolated.
Patients 1–9 - RB assay; 10–17 – OM assay.
Pre-chemotherapy samples.
GeneXpert ASSAY APPLIED TO FILTER INSERTS.
| Clinical Diagnosis | Patient No. | Mask GeneXpert | AFB Smear | Culture |
| Pulmonary TB (UK n = 10) | 18 |
| Sp+++ | Sp + |
| 19 |
| Sp SC | Sp - | |
| 20 |
| Sp+++ | Sp + | |
| 21 |
| Sp SC | Sp + | |
| 22 | + | BAL- | BAL + | |
| 23 |
| BAL++ | BAL + | |
| 24 |
| BAL- | BAL + | |
| 25 |
| Sp- | Sp - | |
| BAL- | BAL + | |||
| 26 |
| BAL- | BAL + | |
| 27 |
| BAL- | BAL - | |
| Extrapulmonary | 28 |
| LN- | LN + |
| 29 |
| PA - | PA + | |
| 30 |
| LN - | LN + | |
| Non-TB (UK n = 6) | 31 |
| Sp - | Sp - |
| 32 |
| Sp - | ND | |
| 33 |
| Sp - | Sp - | |
| 34 |
| Sp - | Sp - | |
| 35 |
| Sp - | Sp - | |
| 36 |
| Sp - | Sp - | |
| Pulmonary TB (Gambia n = 10) | 37 |
| Sp - | Sp + |
| 38 |
| Sp - | Sp - | |
| 39 |
| Sp+++ | Sp + | |
| 40 |
| Sp++ | Sp + | |
| 41 |
| Sp+ | Sp + | |
| 42 |
| Sp+++ | Sp + | |
| 43 |
| Sp+ | Sp + | |
| 44 |
| Sp+++ | Sp + | |
| 45 |
| Sp SC | Sp + | |
| 46 |
| Sp - | Sp + |
BAL = bronchoalveolar lavage; LN = lymph node aspirate, PA = pleural aspirate, Sp = sputum, SC = scanty, ND = Not done.
UK Smear result from local diagnostic service, Gambia smear result from MRC lab. All Gambian patients had a prior smear-positive from their local health clinic.
*All patients diagnosed with extrapulmonary TB were sputum smear- and culture-negative.
Mask collected day 5 of TB treatment.